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Abstract 
Recommended first-line treatment with atypical antipsychotic medication for 
management of schizophrenia and other psychotic disorders is contributory to weight gain and 
associated comorbidities. Beyond comorbid conditions – weight gain can lead to poor self-
image, poor compliance and treatment outcomes in an already stigmatized population. 
Caregivers were selected as participants as they are a primary support in this population. In 
alignment with the Health Belief Model the purpose of this evidence-based intervention was to 
increase risk awareness, increase knowledge of strategies to offset risk, increase confidence and 
self-efficacy and empower health related behaviors among caregivers. Participants were 
identified by providers in an outpatient mental health clinic as caregivers of patients prescribed 
atypical anti-psychotic medications adults aged 18 and above, able to read and understand 
English, and agree to provide consent.  They were asked to (1) complete a demographic and 
knowledge pre-test, gauge perceived knowledge/confidence, (2) view an educational PowerPoint 
focused on atypical anti-psychotic medications, benefits, risks and strategies to mitigate weight-
gain, and (3) complete a knowledge post-test and gauge perceived knowledge/confidence. 
Descriptive statistics were used to examine distribution of variables, due to small sample size, 
Wilcoxon Signed Ranks test was used to compare outcomes.  Qualitative data was also gathered 
to further develop interventions and inform practice.  Comparison between pre- and post-test 
analysis demonstrated improvement in all areas of knowledge, perceived knowledge, and 
perceived confidence.  Statistical analysis demonstrated statistical significance and high practical 
significance.  One-hundred percent of participants recommended the intervention and provided 
qualitive feedback, and suggestions that may be used to inform practice. 
Keywords: schizophrenia, weight, diet, exercise, antipsychotic, intervention, caregiver
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Mitigating Weight Gain with Atypical Antipsychotics 
Individuals with mental illness, specifically schizophrenia, are at an increased risk for 
mortality and morbidity due to the nature of their disease, their lifestyle choices, and side effect 
profile of first line medications (Van Gaal, 2006). Atypical anti-psychotics, also called second 
generation antipsychotics are often prescribed as the preferred treatment for schizophrenia since 
they have a reduced risk for development of extra pyramidal symptoms (EPS) in comparison 
with first-generation antipsychotics. However, the side effect profile of atypical antipsychotic 
medication is such that there is an increased risk for metabolic comorbidities generally following 
the development of weight gain. The overall risk potentiates the development of cardiovascular 
disease, diabetes, decreased energy, and increased stress on the musculoskeletal system (Xiao, 
Baker, & Oyewumi, 2012). The addition of side effects, especially weight gain, further 
jeopardizes well-being already compromised by mental illness or may lead to non-compliance 
which is a detriment to any progress that has been made toward improvement in psychiatric 
symptoms.  Strategies that are designed to mitigate weight gain could offset the physiological 
risk profile and potentially improve compliance and effective management of psychiatric 
symptoms. 
Problem Statement 
Undesirable side effects of atypical antipsychotics such as weight gain, in an already 
compromised population could effectively reduce treatment compliance and thereby efficacy. 
Providers efforts to mitigate risk factors contributing to weight gain could improve treatment 
outcomes by eliminating or significantly reducing undesirable side effects. A meta-analysis 
evaluating numerous approaches to mitigating metabolic side effects revealed that non-
pharmacological interventions including nutrition and exercise programs were effective at 
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reducing weight gain and other risk factors in patients taking antipsychotic medication 
(Caemmerer, Correll, & Maayan, 2012).  Approaches that are supplemental to medication could 
yield a better quality of life by addressing mental and physical well-being. 
Furthermore, patients who are hospitalized or otherwise encounter a provider to address 
symptoms of psychiatric illness have the advantage of a provider and healthcare team present to 
aide in treatment success and recognition of risks and how to mitigate them. These same patients 
are essentially expected to follow treatment guidelines upon discharge or cessation of encounter 
or hospitalization.  However, patients with illness such as schizophrenia requiring treatment with 
atypical antipsychotic medication may already be at a disadvantage when unsupervised due to 
cognitive deficits or otherwise functional impairments.  In order to offset that disadvantage and 
also optimize treatment efforts while mitigating risks it is necessary to capitalize on the use of 
primary supports in the home or residential setting.  This role is generally designated to family or 
other caregivers that have assumed a role of responsibility in caring for the patient but is 
generally not another healthcare provider.  
Purpose and Rationale 
The purpose of this paper is review evidence regarding the contributory factors of weight 
gain in patients taking atypical antipsychotics, and how to incorporate caregiver responsibility in 
efforts to mitigate the development of weight gain by empowering action toward health related 
behaviors.  Current research and literature will be examined to identify strategies that have 
demonstrated efficacy at reducing the incidence and progression of weight gain associated with 
atypical antipsychotics as well as caregiver perception of risk and likelihood of efforts toward 
mitigation.  The rationale for inquiry is to develop a plan for mitigating the undesirable side 
effect of atypical antipsychotic medications that incorporates caregiver support. Interventions 
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aimed at lifestyle modifications including increasing activity and maximizing nutritional intake 
can potentially mitigate risks to overall physical and mental health and well-being. Increasing 
caregiver knowledge of risk and benefit of intervention may increase caregiver support, 
longevity and ongoing success.  
Background and Significance 
External Evidence 
The risk for obesity is 1.5-2 times higher for patients with schizophrenia than in the 
general population, putting them at a greater risk for development of metabolic syndrome which 
is the leading cause for mortality and morbidity among patients with schizophrenia (Bonfioli, 
Berti, Goss, Muraro, & Burti, 2012; Riordan, Antonini, & Murphy, 2011; Xiao et al., 2012).  
Weight gain is the most noticeable sign of metabolic syndrome, is often the most distressing to 
the patient, and is a precursor for additional metabolic side effects such as increased blood 
pressure, triglycerides, and blood glucose (Koch & Scott, 2012).  Additionally, evidence has 
shown a history or diagnosis of schizophrenia can negatively impact treatment determinations 
and referral to supplemental treatment such as weight management (Sullivan et al., 2015).  The 
study indicates that the prejudice is based on the expectation that the patient will be unable to 
effectively adhere to treatment, comprehend education material, manage treatment or make 
appropriate treatment decisions.  Additionally, in the absence of a healthcare provider after 
discharge or cessation of high frequency encounters with a healthcare team, evidence suggests 
that family and caregiver involvement is associated with decreased incidence of relapse, 
maximizing treatment benefits while minimizing risk and improving overall treatment outcomes 
(Britto, 2014; Chovil & Panagiotopoulos, 2010; Eteamah, 2016). The combined evidence 
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suggest that caregiver education is desirable and beneficial to both patients as well as caregivers 
and other key stakeholders in the healthcare community and general population.  
Internal Evidence  
In observation of individuals seeking psychiatric care in an inpatient setting, there is a 
phenomenon of weight gain, specifically relative to patients taking atypical antipsychotic 
medications.  Furthermore, undesirable side effects such as weight gain often precede decreased 
compliance and development of apathy toward continued treatment of schizophrenia, or poor 
management of weight gain and other metabolic side effects leading to a decline in overall 
health. This is also observable in the outpatient setting, especially among patients who are newly 
diagnosed with schizophrenia and have self-reported weight gain despite no reported significant 
changes in their diet.   
Since there is a reasonable expectation of care from the provider, but time with the 
provider is often limited, the responsibility of care translates to lower levels of care that assume 
the role of primary support.  Furthermore, since the responsibility of care is often passed to 
family or other caregivers that are not healthcare providers – there is a reasonable expectation of 
knowledge deficit.  However, empirical evidence in both inpatient and outpatient settings 
demonstrates that caregivers are reaching out, requesting information, and reporting a general 
lack of resources for ongoing support.  
Review 
Multiple sources were reviewed for information regarding caregiver involvement in 
treatment of patients with schizophrenia or other disorders and/or taking atypical antipsychotic 
medication. Evidence indicates that patients with mental illness can be socially isolative which 
limits their propensity toward physical activity and interaction with others outside of their 
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primary support group (Cooper, et al., 2016). Social isolation can be limiting to both 
physiological and psychiatric treatment efficacy which increases the degree to which primary 
support providers such as caregivers or family should have access to the tools needed to be 
effective at managing treatment.  Additionally, evidence suggest that family members and other 
caregivers of patients with schizophrenia and/or taking atypical antipsychotic medication who 
participate in treatment and education programs are interested in learning, report a higher level of 
skill and knowledge after participation, and are better able to monitor and intervene throughout 
the treatment course as needed (Britto, 2014; Chovil & Panagiotopoulos, 2010; Eteamah, 2016).  
If caregivers are seeking information, and able to acquire and accommodate new knowledge – it 
seems prudent to facilitate the instillation of knowledge.   
Since it has been established that there is a health disparity with regard to weigh gain 
related to atypical antipsychotic use and there is evidence to support that caregivers are willing 
and able to participate actively in facilitating successful treatment, it is necessary to review 
approaches to management of weight gain and apply key principles and recommendations to a 
caregiver centered education. To examine effective approaches to management of weight gain, 
multiple studies were reviewed for efficacy.  Deng (2013), suggests that identifying the 
underlying mechanism for the development of symptoms such as weight gain, intra-abdominal 
obesity, glucose dysregulation and insulin resistance is an effective approach to treatment of 
metabolic side effects.  In recognition of the effects of antipsychotics on appetite and weight 
gain, it follows that a program or intervention that addresses these elements can significantly 
reduce the risk potential.  Xiao et al. (2012) introduces several barriers to the management of 
weight gain and development of metabolic side effects identified by patients, including limited 
access to resources, lack of structure in their lifestyle, and the rapidity of the weight gain. 
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Recognizing barriers from the patient perspective is an important consideration in treatment. 
Vanderhoef (2012) examined the healthcare delivery model and follow-up of a provider group 
and suggested that an integrative approach to treatment of seriously mentally ill patients was 
optimal for improving outcomes and successful treatment. An integrative approach in this 
population would address the psychiatric elements while acknowledging the physiological 
impact and providing preventative measures. The integrated approach could include the 
supplementation of pharmacotherapy with nutritional and exercise education. The summary of 
the review of literature indicates information indicates that an effective approach to both the 
treatment of schizophrenia and the management of weight gain associated with first-line 
treatment is multifaceted.  An effective approach includes identification of causative factors, 
consideration of barriers such as access to resources and information, integration of psychiatric 
and physiological elements and inclusion of primary support or caregivers.  
A meta-analysis that reviewed several clinical trials determined that intervention groups 
with a combination of nutritional counseling and exercise show the most substantial reduction in 
weight and associated risk factors (Das, Mendez, Jagasia, Labbate, & National Library of 
Medicine, 2012). Furthermore, lifestyle interventions including dietary and activity 
modifications may be important long-term strategies that decrease the risk of weight gain and the 
compounding metabolic effects that follow (Attux et al., 2013). 
Multiple studies applied principles from PREMIER and DASH comprehensive 
approaches to weight loss or management in sample populations of patients with schizophrenia 
and/or taking atypical antipsychotic medications and found that these approaches were more 
effective at weight management than pharmacological therapy alone (Green et al., 2015; Usher, 
Park, Foster, & Buettner, 2013; Erikson, Mena, Pierre, Blum, & Martin, 2016; Scheewe, Backx, 
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Takken, Jorg, & Van Strater, 2013; Attux et al., 2013).    The format of each program varied 
slightly, however generally compared a control group receiving treatment as usual involving 
pharmacological treatment with antipsychotic medication and informed consent with standard 
review of indications, risks and benefits.  Green et al (2015) and Erikson et al (2016) showed 
evidence that the intervention of dietary and exercise support in addition to standard treatment 
was effective at weight reduction in comparison with control groups.  Another study utilized a 
nurse led intervention program included diet and exercise combined with motivational 
interviewing over a 12-week period.  Other studies involving a similar format yielded results that 
did not demonstrate a statistically significant decrease in weight for the intervention group but 
did indicate a notable increase in weight for the treatment as usual group (Usher, Park, Foster, & 
Buettner, 2013; Scheewe, Backx, Takken, Jorg, & Van Strater, 2013).  Despite insignificant 
weight-loss, outcome measurements in other areas of well-being strongly favored the 
intervention groups (Scheewe et al, 2013).  
The review of literature indicates that there is both evidence supporting the 
implementation of a comprehensive approach to treatment that addresses psychiatric and 
physiological elements and indications that patient outcomes are generally better with the 
involvement of caregiver or primary support.  Since there is a relevant body of evidence 
supporting comprehensive intervention and evidence demonstrating both a caregiver knowledge 
deficit and desire to learn and participate more actively – the provision of an educational 
intervention for caregivers should empower intervention and facilitate treatment success.  
This inquiry has led to the clinically relevant PICOT question: In adult caregivers of 
patient prescribed atypical antipsychotic medication (P), how does an educational intervention (I) 
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compared to no education (C) affect their knowledge, perceived knowledge and self-efficacy 
relative to the content presented to them (T) immediately following presentation delivery? 
Search Process 
To gather evidence regarding the clinical question, an exhaustive search of the literature 
was completed.  Three databases – PubMed, CINAHL and PsycINFO- were searched using the 
keywords (with Boolean connectors) weight (and) antipsychotic (and) intervention (and) exercise 
(or) nutrition.  Restrictions including English language, only human subjects, published between 
2012 and 2017.  Initial yields were reviewed for relevance to PICOT, and outcomes.  Studies that 
included supplementary pharmacological intervention for weight loss were excluded.  Inclusion 
criteria included primary goal of weight reduction or prevention of weight gain and primary 
intervention as education or intervention involving nutritional or activity modifications 
(exercise). Additionally, searching of reference lists within articles yielded additional studies that 
were reviewed for applicability to PICO.  Further searches were conducted to include articles 
and research specifically addressing caregiver involvement in treatment of patients with 
schizophrenia and/or taking atypical antipsychotic medication.  
The PubMed database was assessed using keywords and inclusion criteria and yielded 17 
articles, of which 7 were selected for review (Appendix A). CINAHL database was assessed 
using keywords and inclusion criteria and yielded 7 articles (Appendix B).  After excluding 
duplicate studies, only 1 additional article was selected for further review. PsychINFO database 
was reviewed using the same keywords and search criteria and yielded 21 articles (Appendix C).  
After review for relevance and removal of duplicate items, 2 articles were selected for further 
evaluation. Each study was reviewed independently and for relevance to PICO and pertinent date 
to complete evaluation tables. 
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Critical Appraisal and Synthesis of Evidence 
There were ten articles reviewed regarding the use of interventions to mitigate weight 
gain in patients prescribed atypical antipsychotic medications. The studies included data from 
USA, Brazil, Australia, and the Netherlands with the highest concentration in the USA 
(Appendix F).  All the articles were recently published within the last five years (Appendix D). 
Majority sample selection included males and females age 18 and above, recently started in 
atypical antipsychotic medication for the management of schizophrenia or other related thought 
disorder.  Most of the interventions were in outpatient and community setting, and most involved 
a combination approach to intervention that was compared to standard treatment. Length of 
intervention period were ranged from 6 weeks to 1 year and had a frequency of one or more 
times per week. Level of evidence was strong with design as follows RCT (5), MA (3), PCS (1), 
and RCR (1) (Appendix D).  The meta-analysis (MA) subgroup showed heterogeneity of results 
respective to weight and other factors, especially when intervention categories were variable. 
Conclusions & Discussion 
Non-pharmacological interventions involving lifestyle modifications to diet and exercise 
generate universally better outcomes than control groups offering treatment as usual, generally 
including pharmacological intervention with standard informed consent.  There is some evidence 
that psychotherapeutic interventions such as motivational interviewing or 1:1 counseling may 
increase efficacy of treatment and facilitate more positive outcomes.  Additional article review 
for connection with caregiver involvement in treatment efforts demonstrated that caregivers not 
only had a deficit of knowledge, and wanted to be involved, but that their involvement supported 
overall treatment success and improved treatment outcomes. The evidence supports 
implementation of an intervention that is delivered to caregivers which is aimed at weight loss 
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that includes information regarding dietary modification and increased activity combined with 
ongoing education and follow-up.  Furthermore, outcomes indicate a propensity toward 
successful outcomes and supports a practice change which includes an educational program 
directed toward caregivers as well as patients that targets lifestyle modifications such as diet and 
exercise to offset risks associated with atypical antipsychotic medication.  
Theoretical Framework 
The health belief model is appropriate for an intervention that promotes healthy behavior 
based on education and promotion of awareness of risk potential (Butts & Rich, 2015).  By 
increasing the awareness of indications and risks of atypical antipsychotic medications, the 
identification of both strategies for mitigating the risk of weight gain as well as the benefits 
therein – the increased knowledge and self-efficacy should empower health related behaviors.  
For the purposes of this intervention the empowerment of caregivers to engage in the health 
behavior of aiding those in their care to offset the risks associated with their risk profile of their 
medications. The awareness of risk potential relative to the side effect profile and the long-term 
effects of continued treatment without intervention could be motivating factor.  
Evidence Based Practice Model 
The model for evidence-based practice change, a revised version of the model by 
Rosswurm and Larrabee is appropriate for implementation of an intervention to mitigate weight 
gain in patients taking atypical antipsychotics (Melnyk & Fineout-Overholt, 2015).  As indicated 
in the model (Appendix E), there is an identified need for a change in practice based on internal 
evidence and compiled high-level external evidence respective of the nature of the problem and 
common intervention strategies that have proven successful.  In moving forward development of 
an intervention involving caregiver education regarding atypical antipsychotic medication – 
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indications, risks (i.e. weight gain), strategies to mitigate risk and benefits of intervention. 
Implementation and evaluation of change with positive immediate outcome – increased 
knowledge and self-efficacy -  should facilitate empowerment to engage in health related 
behaviors and perpetuate the practice change.  This is an appropriate model for this intervention 
as it translates synthesis of evidence and critical thought into a change in practice that is patient 
centered while still benefiting key stakeholders. The initial steps have been completed within the 
synthesis of current evidence supporting the significance of the problem and effective 
intervention strategies. IRB approval was obtained following submission of proposal and project 
has been successfully implemented within the target population.  Further study and analysis 
could be generated from successful application of learned information into the patient population 
and perpetuated. 
Proposed EBP 
Project Outline  
Proposed intervention is aimed at increasing the knowledge and self-efficacy of 
caregivers by providing an evidence based educational intervention introducing information 
about treatment with atypical antipsychotic medication.  Specific education is provided relative 
to indications for atypical antipsychotic medication use, risks associated with use with specific 
attention to weight gain and associated comorbidities, followed by evidence-based strategies for 
mitigating weight gain with specific focus on monitoring, dietary modifications, and increasing 
activity.  This intervention is aligned with external evidence that supports the use of education 
regarding disease management and prevention (Attux et al., 2013; Caemmerer et al., 2012; Das 
et al., 2012; Erikson, Mena, Pierre, Blum, & Martin, 2016; Green et al., 2015; Scheewe et al., 
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2013; Usher et al., 2013; Vanderhoef, 2012).  Intervention had a total duration of approximately 
1-2 hours allowing for introduction, pre-test, educational powerpoint, questions and post-test.   
    Fortunately, there were not many obstacles to overcome.  There was an initial delay in 
recruitment due to IRB approval, however once approved recruitment was smooth and efficient.  
Other potential complication with the use of survey and educational material is literacy and 
understanding of content – fortunately the very few misunderstandings were clarified and did not 
have an impact on time or results.  
Methods 
Design 
The study design was quasi-experimental, one group, pre-test and post-test and based on 
the Model for Evidence Based Practice change by Rosswurm and Larrabee and the Health Belief 
Model (Melnyk & Fineout-Overholt, 2015; Butts & Rich, 2015). 
Sample and Sampling 
A convenience sample of 15 participants were recruited from a small outpatient 
psychiatric clinic in Goodyear, Arizona. The inclusion criteria were adults age 18 and above who 
(1) identify themselves as primary caregivers of patients taking atypical antipsychotic medication 
for psychotic disorders and receive treatment from Agape Family clinic; (2) are able to read, 
write and understand English; (3) agree to provide consent. Individuals who do not meet all 
inclusion criteria or decline participation would be excluded.   
Procedure 
Caregivers were identified in collaboration with psychiatric providers. Caregivers who 
were interested in participation contacted the author via information provided on flyer. The 
author also contacted potential participants identified and referred by psychiatric providers. 
MITIGATING WEIGHT GAIN 15 
During initial interaction the author introduced herself, the purpose of the project, procedure and 
potential risks and benefits of participating in the project. Caregivers who consented to 
participate were enrolled.  
Eligible caregivers who consented were invited to a one-hour educational presentation 
held in the clinic. They completed a short pretest survey including demographic information, 
followed by a PowerPoint presentation delivered by the author, then completed the post-test 
survey. The PowerPoint presentation included content regarding indications, potential side-
effects, risks and benefits of atypical antipsychotic medications, and strategies to reduce side 
effects especially weight gain associated with these medications. Participants were given the 
opportunity to ask questions during the presentation. The pretest and posttest surveys were brief 
(5-10 minutes each to complete), anonymous and linked by a nickname created by participants.    
Measures 
Sociodemographic information, knowledge assessment, perceived knowledge, perceived 
self-efficacy, and project evaluation. 
1. Sociodemographic information – questions asked each patients age, biological 
sex, highest educational level, relationship to patient, duration of providing care, observation of 
weight gain, and names of medications taken by patient.  These questions were asked in pretest 
only.  
2. Knowledge assessment -  included 6 questions assessing participant knowledge of 
relative information based on content of PowerPoint presentation.  The questions were multiple 
choice with only one correct answer for each question.  The same 6 knowledge assessment 
questions were asked on pre- and post-tests for comparison.   
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3. Perceived knowledge self-assessment – included one question assessing perceived 
knowledge with a scaled format ranging from little to no knowledge, somewhat knowledgeable, 
more knowledgeable than most people I know and expert knowledge.  The same question was 
asked on pre- and post-test for comparison. 
4. Perceived self-efficacy – included one question assessing perceived knowledge 
with a scale format ranging from not confident at all, a little bit confident, confident and very 
confident.  The same question was asked on pre- and post-tests for comparison. 
5. Project evaluation – included 3 questions assessing perceived benefits, 
recommendation of presentation and additional suggestions.  The questions were open ended for 
feedback.  
Data Analysis 
Descriptive statistics were used to describe sample characteristics and examine 
distribution of variables.  Non-parametric methods were used due to small sample size in which 
normal distribution of data is not assumed (Kellar & Kelvin, 2013).  Wilcoxon Signed Ranks test 
was used to compare data collected at pretest and posttest. Cohen’s D coefficient was used to 
calculate effect size where small effect size is 0.2, moderate effect size is 0.5, and large effect 
size is 0.8 (Kellar & Kelvin, 2013).  
Results 
Sample Characteristics 
A total of 15 adult participants (66% female, 33% age 18-29, 33% age 40-49, 40% 
completed high-school) completed the education and pre- and post-test.  About 67% of them 
identified themselves as a parent or other caregiver.  The mean duration for a patient taking 
atypical antipsychotic medication is 6 years.  About 33.3% of patients were reportedly taking 
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Risperdal, 26.7% taking Seroquel, 26.7% taking Zyprexa, 6.7% taking Abilify, and 6.7% taking 
more than one atypical antipsychotic medication.  All participants reported weight gain in 
patients after starting the identified medications.  
Measures 
The mean pre-intervention knowledge score was 3.33 (SD = 1.88, range = 0-6).  The 
mean post-intervention knowledge score was 5.86 (SD = 0.52, range = 0-6).  Findings from the 
Wilcoxon Signed Ranks test indicated the change (Z=-3.077, p=0.002) was statistically 
significant.  Findings from Cohen’s effect size value (d= 1.3) suggest large effect size and high 
practical significance.  
Perceived Level of Knowledge  
The mean pre-intervention score for perceived knowledge was 1.6 (1=little to no 
knowledge, 2= somewhat knowledgeable, 3= more knowledgeable than most people I know, 4= 
Very knowledgeable).  About 40% of participants indicating 1 (little to no knowledge) and 60% 
percent indicating 2 (somewhat knowledgeable) relative to their perceived knowledge of the 
content.  The mean post intervention score for knowledge was 2.8, 20% of participants indicating 
2 (somewhat knowledgeable) and 80 percent indicating 3 (more knowledgeable that most people 
I know).  Wilcoxon Signed Ranks test indicated the change (Z=-3.448, p=0.001) was statistically 
significant.  Findings from Cohen’s effect size value (d=2.1) suggest large effect size and high 
practical significance. 
Perceived Confidence 
The mean pre-intervention score for perceived confidence was 1.93 suggesting between 
not confident and a little bit confident (1=not confident, 2=a little bit confident, 3=confident, 
4=very confident).  About 53.3% of participants indicated 2 (a little bit confident), 26.7% of 
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participants indicated 1 (not confident) and 20% of participants indicated 3 (confident) relative to 
their perceived confidence in the subject area and applying intervention.  The mean post-
intervention score for perceived confidence was 3.4 with 46.7 percent of participants indicating 4 
(very confident), 46.7% of participants indicating 3 (confident) and 6.7% of participants 
indicating 2 (somewhat confident).  Wilcoxon Signed Ranks test indicated that the change from 
pre-test to post-test scores (Z=-3.376, p=0.001) was statistically significant.  Findings from 
Cohen’s effect size value (d=1.8) suggest a large effect size and high practical significance. 
Project Evaluation 
Participants were invited to evaluate the educational presentation and overall 
intervention.  All (100%) of participants responded that they would recommend this presentation 
to others.  When asked to provide rationale for their response to their recommendation they felt it 
was helpful to discuss indications of the medications, timing and onset of weight gain, 
cardiovascular risks, and health benefits of changes in diet and exercise.  They also found it 
helpful to learn strategies to help patients manage their weight while taking antipsychotic 
medications.  The participants suggested to offer this presentation to “everyone”. “all new 
patients”, “including more examples of food choices and food logs”, and “rewording some 
questions”. 
Discussion 
The potential short-term implications for practice change include the implementation of 
similar educational interventions for caregivers in similar and other practice settings.  
Additionally, as recommended by participants – inclusion of patients in similar structured 
educational intervention would also be useful.  The short term-benefit for participants is the 
actual increase in knowledge and confidence and resultant empowerment to act.  The use of 
MITIGATING WEIGHT GAIN 19 
small group intervention alleviates the need for separate additional time to be accommodated 
into an already busy schedule, and the presence of groups of individuals with similar needs helps 
build an additional secondary support network while also allowing providers to keep current with 
the questions and concerns within their target population.   
Intermediate or long-term implications that result from the empowerment of participants 
is the actual implementation within the patient population of learned interventions potentially 
yielding less incidence of weight gain and the development of metabolic comorbidities which 
translates to improved treatment outcomes, less medication changes, decreased need for face 
time, decreased need for coordination of care with specialized providers and overall 
improvement in well-being. Future dissemination of evidence is planned for other similar 
outpatient mental health providers and at a local conference. 
Conclusion 
The overall efforts of this evidence-based intervention were inspired by the need to 
mitigate the weight gain associated with use of atypical antipsychotic medication.  Since this is 
the first line medication choice for schizophrenia and other similar disorders which already carry 
an increased risk for mortality and morbidity, and an increased risk for weight and metabolic 
disorders -there is a unique dilemma. Furthermore, many patients are stabilized and treated on an 
outpatient basis without ongoing high frequency support and direction of a healthcare team 
leaving an already vulnerable individual essentially more vulnerable with additional risks.  The 
dilemma then is to effectively manage psychiatric condition while mitigating the development of 
a physiological one without the daily support of a healthcare provider.  The intervention utilized 
for this project was to provide education to caregivers – the effective primary support person for 
patients with schizophrenia needing additional support.  Following the health belief model, the 
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increase in knowledge and self-efficacy, will empower individuals to engage in health-related 
behaviors.  While it is unknow at this time the frequency of enactment of learned information – 
data analysis demonstrates statistical significance and high practical significance relative to 
improvements in knowledge, perceived knowledge and perceived confidence which is certainly 
promising and yields future implications to gather data and analyze applied principles and patient 
outcomes.  As providers we should hold ourselves accountable to providing our patients with the 
best opportunity possible to achieve treatment success without being a detriment to other area of 
functioning. Interventions similar to this one provides additional educational support and 
empowerment of primary supports in the absence of a provider or healthcare team.  
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Year 2013 2012 2016 2012 2016 2015 2012 2013 2013 2013 
LOE II I I II I II II IV II II 
Design RCT MA MA PCS MA RCT RCT RCR RCT RCT 







Diet X X X X X X X   X 
Exercise X X X X X X X  X X 
MI  X   X      
Diary     X X X    






Weight v v ^ ^ v v v   V 
BMI v  ^ ^ v    v  
WC   ^ ^ v    v V 
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1:1 – Support from clinician/nurse; ACT -activity session or education; AP – Antipsychotic medication; BGL -blood glucose level; BMI- Body Mass Index; CG 
– control group; CI – Confidence Interval; DV-dependent variable; EDUC – education/book/pamphlet; ET – Exercise Therapy; HDLC -High Density 
Lipoprotein Cholesterol; IG – Intervention group; IV- independent variable; LDLC – Low density Lipoprotein Cholesterol; LWP – Lifestyle Wellness Program; 
MetS -Metabolic Syndrome; N-number of studies; n- number of participants; ; NNT -Number Needed to Treat; NPhI – Non-Pharmacological Interventions; 
NRCT – Non-randomized controlled trial; NUT – Nutritional education; OT – Occupational Therapy; PBF – Percent body fat; RCT- Randomized Controlled 
Trial; RR – Risk Ratio; SBP – Systolic Blood Pressure; TAU – Treatment as usual; TC – Total cholesterol; TRI- Triglycerides; WC – Waist circumference; 





























to test the 
























Purpose: to test 






Weight and BMI  
n= 160 patients 
participated in the study 
(81 in the IG and 79 in 
the CG group). 
 
Inclusion Criteria: 
Participants using any 
antipsychotic in the past 
three months, diagnosis 
on the schizophrenia 
spectrum age 18 to 65 
years old, and being 
clinical stable, i.e., 
reaching less than 60 in 
the Positive and 
Negative Syndrome 
Scale (PANSS) scale 
 
Exclusion Criteria: 
not clinically stable, 
history of an eating 
disorder (Anorexia and 
Bulimia), history of 
drug and alcohol abuse. 
Patients taking 
medication for 





DV1 – Weight 






square tests - 
















IG= - 0.48 kg (CI 95% -
0.65 to 1.13)  
CG = + 0.48 kg (CI 
95% 0.13 to 0.83; 
p=0.055).  
@6months 
IG= −1.15 kg, (CI 95% 
-2.11 to 0.19)  
CG= +0.5 kg 
 (CI 95% -0.42–1.42, 
p=0.017). 
 
IG had a mean weight 
decrease of 1.15 kg, 
while CG had a mean 
weight increase of 0.5 
kg which was determine 
to be statistically 











sizes and increase 
intervention and 
follow up time 
could increase 
efficacy and 
improve results.  
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1:1 – Support from clinician/nurse; ACT -activity session or education; AP – Antipsychotic medication; BGL -blood glucose level; BMI- Body Mass Index; CG 
– control group; CI – Confidence Interval; DV-dependent variable; EDUC – education/book/pamphlet; ET – Exercise Therapy; HDLC -High Density 
Lipoprotein Cholesterol; IG – Intervention group; IV- independent variable; LDLC – Low density Lipoprotein Cholesterol; LWP – Lifestyle Wellness Program; 
MetS -Metabolic Syndrome; N-number of studies; n- number of participants; ; NNT -Number Needed to Treat; NPhI – Non-Pharmacological Interventions; 
NRCT – Non-randomized controlled trial; NUT – Nutritional education; OT – Occupational Therapy; PBF – Percent body fat; RCT- Randomized Controlled 
Trial; RR – Risk Ratio; SBP – Systolic Blood Pressure; TAU – Treatment as usual; TC – Total cholesterol; TRI- Triglycerides; WC – Waist circumference; 




















































































diet and physical 
activity shows a mean 
BMI reduction of 0.98, 
corresponding to a 
weight reduction of 
3.12% of initial weight.  
3.12% < NIH 
guidelines, but still 
sufficient to show 
improvement 
 
Results indicated an 
effect toward 
experimental groups 
with a greater mean 
reduction in BMI  
 
95% CI:  












missing data and 
compensation for 
participants in 





sample size, more 
in depth analysis 
of data with 
additional 
controls for bias a 
heterogeneity 
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1:1 – Support from clinician/nurse; ACT -activity session or education; AP – Antipsychotic medication; BGL -blood glucose level; BMI- Body Mass Index; CG 
– control group; CI – Confidence Interval; DV-dependent variable; EDUC – education/book/pamphlet; ET – Exercise Therapy; HDLC -High Density 
Lipoprotein Cholesterol; IG – Intervention group; IV- independent variable; LDLC – Low density Lipoprotein Cholesterol; LWP – Lifestyle Wellness Program; 
MetS -Metabolic Syndrome; N-number of studies; n- number of participants; ; NNT -Number Needed to Treat; NPhI – Non-Pharmacological Interventions; 
NRCT – Non-randomized controlled trial; NUT – Nutritional education; OT – Occupational Therapy; PBF – Percent body fat; RCT- Randomized Controlled 
Trial; RR – Risk Ratio; SBP – Systolic Blood Pressure; TAU – Treatment as usual; TC – Total cholesterol; TRI- Triglycerides; WC – Waist circumference; 






















effects of NPhI 
for AP 
associated 
























Potential bias – 
research 
supported by 






















weight gain and 
other risk factors 
N= 17 
n=810 







Inclusion Criteria: RCT, 
addresses antipsychotic 





data, use of 
pharmacological agent 




DV2 – BMI 
DV3 – HDLC 
DV4 - LDLC 
DV5 – SBP 
DV6 – WC 
DV7 – PBF 
DV8 – GLU 
DV9 – Insulin 
DV10 – TC 
DV11 - TRI 
 
IV- NPhI 
Data were analyzed 
using randomized 
effects models in 
Review Manager 
5.0 
All tests were 
two-sided and 



























NPhI = WT − 3.12 kg; 
CI: − 4.03, − 2.21, 
p < 0.0001)  
BMI= − 0.94 kg/m2; CI: 
− 1.45, − 0.43, 
p = 0.0003) 
 
 WC = − 3.58 cm, CI: 
− 5.51, − 1.66, 
p = 0.03), 
PBF = − 2.82%, CI: 
− 5.35, − 0.30, 
p = 0.03), 
GLU = − 5.79 mg/dL, 
CI: − 9.73, − 1.86, 
p = 0.004) 
Insulin 
= − 4.93 uIU/mL, CI: 
− 7.64, − 2.23, 
p = 0.0004 
TC = − 20.98 mg/dL, 
CI: − 33.78, − 8.19; 
p = 0.001) 
LDLC = − 22.06 mg/dL, 
CI: − 37.80, − 6.32, 
p = 0.006 
TRI = − 61.68 mg/dL, 
CI: − 92.77, − 30.59, 
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1:1 – Support from clinician/nurse; ACT -activity session or education; AP – Antipsychotic medication; BGL -blood glucose level; BMI- Body Mass Index; CG 
– control group; CI – Confidence Interval; DV-dependent variable; EDUC – education/book/pamphlet; ET – Exercise Therapy; HDLC -High Density 
Lipoprotein Cholesterol; IG – Intervention group; IV- independent variable; LDLC – Low density Lipoprotein Cholesterol; LWP – Lifestyle Wellness Program; 
MetS -Metabolic Syndrome; N-number of studies; n- number of participants; ; NNT -Number Needed to Treat; NPhI – Non-Pharmacological Interventions; 
NRCT – Non-randomized controlled trial; NUT – Nutritional education; OT – Occupational Therapy; PBF – Percent body fat; RCT- Randomized Controlled 
Trial; RR – Risk Ratio; SBP – Systolic Blood Pressure; TAU – Treatment as usual; TC – Total cholesterol; TRI- Triglycerides; WC – Waist circumference; 

































provided by a 
research grant 








































weight gain  
n= 28 
IG-16 
TAU - 12 
 
Inclusion Criteria: 







brief psychotic disorder, 
bipolar affective 
disorder, or depression 
with psychotic features 
and treatment with 
antipsychotic 
medication for less than 




medically unfit to 
exercise as determined 




for longer than 4 weeks. 
DV1 – Weight 
DV2- BMI 
DV3 – HDLC 
DV4 - LDLC 
DV5 – BP 
DV6 – WC 
DV7 –  
DV8 – BGL 
DV9 – Insulin 
DV10 – TC 
DV11 – TRI 
 
IV1 - health 
coaching 
IV2 - dietetic 
support 
IV3 - supervised 
exercise 
prescription 
IV4 – Peer 
Support 












IG= WT +1.8 kg (95% 
CI −0.4 to 2.8) 










IG = + 0.1 cm (−2.1 to 
2.2)  
CG= +7.1 cm (4.8–10.7) 
LOE: II 
Limitations: 
Short term follow 
up, small sample 
size 
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1:1 – Support from clinician/nurse; ACT -activity session or education; AP – Antipsychotic medication; BGL -blood glucose level; BMI- Body Mass Index; CG 
– control group; CI – Confidence Interval; DV-dependent variable; EDUC – education/book/pamphlet; ET – Exercise Therapy; HDLC -High Density 
Lipoprotein Cholesterol; IG – Intervention group; IV- independent variable; LDLC – Low density Lipoprotein Cholesterol; LWP – Lifestyle Wellness Program; 
MetS -Metabolic Syndrome; N-number of studies; n- number of participants; ; NNT -Number Needed to Treat; NPhI – Non-Pharmacological Interventions; 
NRCT – Non-randomized controlled trial; NUT – Nutritional education; OT – Occupational Therapy; PBF – Percent body fat; RCT- Randomized Controlled 
Trial; RR – Risk Ratio; SBP – Systolic Blood Pressure; TAU – Treatment as usual; TC – Total cholesterol; TRI- Triglycerides; WC – Waist circumference; 









































































Sample sizes and setting 





























CI = 95% 
Behavioral therapies to 
treat weight gain 
associated with AP have 
had the most consistent 
beneficial results. 
Among the behavioral 
therapies, nutritional 
counseling combined 








Indicative of the 
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1:1 – Support from clinician/nurse; ACT -activity session or education; AP – Antipsychotic medication; BGL -blood glucose level; BMI- Body Mass Index; CG 
– control group; CI – Confidence Interval; DV-dependent variable; EDUC – education/book/pamphlet; ET – Exercise Therapy; HDLC -High Density 
Lipoprotein Cholesterol; IG – Intervention group; IV- independent variable; LDLC – Low density Lipoprotein Cholesterol; LWP – Lifestyle Wellness Program; 
MetS -Metabolic Syndrome; N-number of studies; n- number of participants; ; NNT -Number Needed to Treat; NPhI – Non-Pharmacological Interventions; 
NRCT – Non-randomized controlled trial; NUT – Nutritional education; OT – Occupational Therapy; PBF – Percent body fat; RCT- Randomized Controlled 
Trial; RR – Risk Ratio; SBP – Systolic Blood Pressure; TAU – Treatment as usual; TC – Total cholesterol; TRI- Triglycerides; WC – Waist circumference; 


















































































Greater than or equal to 
7% weight increase 





DV = Weight 




DV4 = health 
knowledge 
DV5 = HgA1c 
DV6 = BGL 
DV7 = lipid 
levels 
 





counseling for 8 





















in predicted trajectory 
of mean WT change 
between the groups over 
12 months (P &lt; .01), 
with treatment 
participants expected to 
lose an average 4.6 kg, 
while control 
participants would gain 
an average 0.6 kg. BMI 
and body fat percentage 
followed the same 
pattern. Both groups 
demonstrated 
statistically significant 
improvements in health 
knowledge quiz scores 








than usual care 













effective in SMI 
patients 
Citation Theory/ Design/ Method Sample/ Setting Major Variables Measurement/ Data Analysis Findings/ Level/Quality of 
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1:1 – Support from clinician/nurse; ACT -activity session or education; AP – Antipsychotic medication; BGL -blood glucose level; BMI- Body Mass Index; CG 
– control group; CI – Confidence Interval; DV-dependent variable; EDUC – education/book/pamphlet; ET – Exercise Therapy; HDLC -High Density 
Lipoprotein Cholesterol; IG – Intervention group; IV- independent variable; LDLC – Low density Lipoprotein Cholesterol; LWP – Lifestyle Wellness Program; 
MetS -Metabolic Syndrome; N-number of studies; n- number of participants; ; NNT -Number Needed to Treat; NPhI – Non-Pharmacological Interventions; 
NRCT – Non-randomized controlled trial; NUT – Nutritional education; OT – Occupational Therapy; PBF – Percent body fat; RCT- Randomized Controlled 
Trial; RR – Risk Ratio; SBP – Systolic Blood Pressure; TAU – Treatment as usual; TC – Total cholesterol; TRI- Triglycerides; WC – Waist circumference; 
WMD – Weighted Mean Difference 
Conceptual 
Framework 


























































and diabetes risk 
n= 200 
Men = 56 
Women = 144 
Mean age 47.2 years 
IG = 104 
TAU = 96 
n= 181 @ 6 months 
n= 170 @12 months 
 
inclusion criteria: 
18+ years old 













DV = Weight 


















Wald Test IG lost 4.4 kg more than 
CG at 6 months 
 
IG lost 2.6 kg more than 














duration of the 
intervention is an 
important first 
step 
Citation Theory/ Design/ Method Sample/ Setting Major Variables Measurement/ Data Analysis Findings/ Level/Quality of 
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1:1 – Support from clinician/nurse; ACT -activity session or education; AP – Antipsychotic medication; BGL -blood glucose level; BMI- Body Mass Index; CG 
– control group; CI – Confidence Interval; DV-dependent variable; EDUC – education/book/pamphlet; ET – Exercise Therapy; HDLC -High Density 
Lipoprotein Cholesterol; IG – Intervention group; IV- independent variable; LDLC – Low density Lipoprotein Cholesterol; LWP – Lifestyle Wellness Program; 
MetS -Metabolic Syndrome; N-number of studies; n- number of participants; ; NNT -Number Needed to Treat; NPhI – Non-Pharmacological Interventions; 
NRCT – Non-randomized controlled trial; NUT – Nutritional education; OT – Occupational Therapy; PBF – Percent body fat; RCT- Randomized Controlled 
Trial; RR – Risk Ratio; SBP – Systolic Blood Pressure; TAU – Treatment as usual; TC – Total cholesterol; TRI- Triglycerides; WC – Waist circumference; 
WMD – Weighted Mean Difference 
Conceptual 
Framework 


















































purpose of this 
study was to 
determine if 
treatment 









type 2 diabetes 









bipolar disorder, mood 
disorder not otherwise 
specified or 
psychotic disorder not 
otherwise specified 




















IV2 - practitioner 
preference 




CI – 95% 
P<0.05 
The use of EBP 
guidelines demonstrated 
a reduction in risk and 
incidence of factors 
associated with 
metabolic MetS, 
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1:1 – Support from clinician/nurse; ACT -activity session or education; AP – Antipsychotic medication; BGL -blood glucose level; BMI- Body Mass Index; CG 
– control group; CI – Confidence Interval; DV-dependent variable; EDUC – education/book/pamphlet; ET – Exercise Therapy; HDLC -High Density 
Lipoprotein Cholesterol; IG – Intervention group; IV- independent variable; LDLC – Low density Lipoprotein Cholesterol; LWP – Lifestyle Wellness Program; 
MetS -Metabolic Syndrome; N-number of studies; n- number of participants; ; NNT -Number Needed to Treat; NPhI – Non-Pharmacological Interventions; 
NRCT – Non-randomized controlled trial; NUT – Nutritional education; OT – Occupational Therapy; PBF – Percent body fat; RCT- Randomized Controlled 
Trial; RR – Risk Ratio; SBP – Systolic Blood Pressure; TAU – Treatment as usual; TC – Total cholesterol; TRI- Triglycerides; WC – Waist circumference; 
WMD – Weighted Mean Difference 
















































objective of this 
multicenter 
randomised 
clinical trial was 
to examine the 









ET = 31 
OT = 32 
 
Inclusion:  
IQ > 70 
diagnosed with 
schizophrenia (n = 45), 
schizoaffective (n = 15), 
or schizophreniform 
disorder (n = 3), stable 
on AP, taking the same 
dosage for at least 4 
weeks prior to inclusion  
 
Exclusion 
Primary diagnosis of 
substance abuse or 
alcoholism 
Evidence of significant 
cardiovascular, 
neuromuscular, 
endocrine or somatic 
disorder preventing safe 
participation in the 
study 
DV1 - CV 
DV2 – MHSS 
Schizophrenia 
DV3 – MHSS 
Depression 
DV5 - BMI  
DV6 - PBF  
DV - MetS 
 
IV1 – ET 
IV2 - OT 
cardiovascular 
fitness levels as 
































analyses showed ET had 
a trend-level effect on 
depressive symptoms (P 
= 0.07) and a significant 
effect on cardiovascular 
fitness, measured by 
Wpeak (P < 0.01), 
compared with OT. Per 
protocol analyses 
showed that ET reduced 
symptoms of 
schizophrenia (P = 
0.001), depression (P = 
0.012), need of care (P 
= 0.050), and increased 
cardiovascular fitness (P 
< 0.001) compared with 
OT. No effect for MetS 
(factors) was found 
except a trend reduction 








size and duration 
of treatment and 
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1:1 – Support from clinician/nurse; ACT -activity session or education; AP – Antipsychotic medication; BGL -blood glucose level; BMI- Body Mass Index; CG 
– control group; CI – Confidence Interval; DV-dependent variable; EDUC – education/book/pamphlet; ET – Exercise Therapy; HDLC -High Density 
Lipoprotein Cholesterol; IG – Intervention group; IV- independent variable; LDLC – Low density Lipoprotein Cholesterol; LWP – Lifestyle Wellness Program; 
MetS -Metabolic Syndrome; N-number of studies; n- number of participants; ; NNT -Number Needed to Treat; NPhI – Non-Pharmacological Interventions; 
NRCT – Non-randomized controlled trial; NUT – Nutritional education; OT – Occupational Therapy; PBF – Percent body fat; RCT- Randomized Controlled 
Trial; RR – Risk Ratio; SBP – Systolic Blood Pressure; TAU – Treatment as usual; TC – Total cholesterol; TRI- Triglycerides; WC – Waist circumference; 
WMD – Weighted Mean Difference 


























and a grant 


















Purpose: To test 
the effect of a 
nurse-led 
intervention on 










CG = 51 
IG = 50 
 
Setting was variable 
 
Inclusion Criteria: 
a diagnosis of serious 
mental illness, 18 years 
of age or older, not 
currently psychotic, 
prescribed and taking 
second generation 
antipsychotic 
medication, living in 
North Queensland, and 




DV1 – WT 
DV2 – WC 
DV3 – BMI 
 
IV1 – EDUC  
IV2 – ACT 
IV3 – NUT 











had a mean WT loss of 
0.74 kg 
WC - 0.23 cm 
BMI -0.25 kg/m2 
CG  
had a mean WT loss of 
0.17kg 
WC – 0.15cm 
BMI – 0.06 kg/m2 
 
statistical analysis 







short duration, not 
blinded, location, 
no gauge for 
comprehension 
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